Artielle Immunotherapeutics is pioneering a first-in-class biologic platform to treat neuroinflammatory and neurodegenerative diseases, based on foundational research from Oregon Health & Science University.
Artielle Immunotherapeutics is a venture-backed company headquartered in Portland, OR. We are developing a novel, first-in-class biologic to treat a range of inflammatory and neurodegenerative diseases based on research from Oregon Health & Science University (OHSU).
Artielle is preparing DRhQ, its second-generation molecule, for Phase I/II trials in collaboration with academic institutions including OHSU for methamphetamine use disorder and multiple sclerosis (MS). Support for developing DRhQ as a therapeutic includes its efficacy in animal models and the successful completion of a Phase I clinical trial in patients with MS using the first-generation molecule.
Multiple sclerosis, brain trauma, stroke, substance use disorder (SUD), and neurodegenerative and autoimmune diseases that cause damage to the central nervous system (CNS) may have catastrophic consequences. Unfortunately, there are few effective treatments available that can ameliorate these conditions once the initial damage has occurred.
Artielle works closely with Virogenomics BioDevelopment, Inc. (VBD) on preclinical drug development. Renee Shirley, Ph.D., a founder of the company, directs VBD's research and business strategy. VBD has been awarded over $10M in NIH funding to develop DRhQ for methamphetamine use disorder, which includes IND-enabling studies and Phase I/II clinical trials.
Venture-backed, headquartered in Portland, OR
Research platform based on OHSU discoveries
Phase I safety study completed (RTL1000 in MS)
DRhQ preparing for Phase I/II trials in SUD
4 active disease indications targeted
$10M+ NIH funding secured through partner VBD